company background image
ADCT logo

ADC Therapeutics NYSE:ADCT Stock Report

Last Price

US$4.20

Market Cap

US$346.6m

7D

-11.2%

1Y

94.4%

Updated

27 Mar, 2024

Data

Company Financials +

ADCT Stock Overview

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADCT fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

ADC Therapeutics SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ADC Therapeutics
Historical stock prices
Current Share PriceUS$4.20
52 Week HighUS$6.04
52 Week LowUS$0.36
Beta1.76
1 Month Change-18.29%
3 Month Change164.15%
1 Year Change94.44%
3 Year Change-82.79%
5 Year Changen/a
Change since IPO-85.83%

Recent News & Updates

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

Mar 19

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

Mar 17
ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

Jan 18
ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

Recent updates

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)

Mar 19

ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

Mar 17
ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues

ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

Jan 18
ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth

ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial

Dec 29

An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

Dec 14
An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued

ADC Therapeutics: Navigating A Swirling Drain

Dec 01

ADC Therapeutics: Slowly Moving Toward Solvency

Aug 29

Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?

Jul 11
Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?

ADC Therapeutics: Maybe A 2024 Story

May 29

Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

May 11
Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%

ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

Apr 18
ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business

ADC Therapeutics stock slips after pricing stock offering by seller

Feb 02

Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

Jan 16
Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?

Jose Carmona joins ADC Therapeutics as CFO

Dec 19

ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M

Nov 08

ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval

Sep 16

ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11

Sep 09

ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M

Aug 09

Analysts Just Made A Meaningful Upgrade To Their ADC Therapeutics SA (NYSE:ADCT) Forecasts

Jul 21
Analysts Just Made A Meaningful Upgrade To Their ADC Therapeutics SA (NYSE:ADCT) Forecasts

Sobi to pay ADC Therapeutics $55M upfront to license Zynlonta in Europe, other regions

Jul 08

ADC Therapeutics begins dosing in study of Zynlonta combo for blood cancer subtype

Jun 29

Is ADC Therapeutics (NYSE:ADCT) A Risky Investment?

Jun 22
Is ADC Therapeutics (NYSE:ADCT) A Risky Investment?

ADC Therapeutics SA (NYSE:ADCT) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 06
ADC Therapeutics SA (NYSE:ADCT) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Growth Investors: Industry Analysts Just Upgraded Their ADC Therapeutics SA (NYSE:ADCT) Revenue Forecasts By 21%

Mar 05
Growth Investors: Industry Analysts Just Upgraded Their ADC Therapeutics SA (NYSE:ADCT) Revenue Forecasts By 21%

Shareholder Returns

ADCTUS BiotechsUS Market
7D-11.2%-0.5%0.6%
1Y94.4%9.6%29.5%

Return vs Industry: ADCT exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: ADCT exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is ADCT's price volatile compared to industry and market?
ADCT volatility
ADCT Average Weekly Movement16.2%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: ADCT's share price has been volatile over the past 3 months.

Volatility Over Time: ADCT's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2011274Ameet Mallikhttps://www.adctherapeutics.com

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

ADC Therapeutics SA Fundamentals Summary

How do ADC Therapeutics's earnings and revenue compare to its market cap?
ADCT fundamental statistics
Market capUS$346.62m
Earnings (TTM)-US$240.05m
Revenue (TTM)US$69.56m

5.0x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ADCT income statement (TTM)
RevenueUS$69.56m
Cost of RevenueUS$125.71m
Gross Profit-US$56.15m
Other ExpensesUS$183.91m
Earnings-US$240.05m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.91
Gross Margin-80.72%
Net Profit Margin-345.11%
Debt/Equity Ratio-280.8%

How did ADCT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.